Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Rapamycin is an immunosuppressant with anti-inflammatory properties, used for autoimmune diseases.
• Experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice serves as a model for multiple sclerosis (MS).
• The mammalian target of rapamycin (mTOR) signaling pathway is implicated in immune cell activation.

Purpose of the Study:

• To investigate the mechanism of rapamycin's action in an EAE mouse model.
• To determine rapamycin's effect on the mTOR-STAT3 pathway and T helper cell subsets in EAE.

Main Methods:

• Administration of rapamycin to C57BL/6 mice with EAE.
• Assessment of clinical scores and spinal cord inflammatory cell infiltration.
• Measurement of mTOR-STAT3 pathway markers (p-mTOR/mTOR, p-STAT3/STAT3), T helper cell proportions (Th1, Th17), transcription factors (T-bet, RoRγt), and cytokine levels (IFN-γ, IL-17).

Main Results:

• Rapamycin significantly reduced EAE clinical scores and spinal cord inflammation.
• Rapamycin reversed EAE symptoms and suppressed the mTOR-STAT3 pathway.
• Rapamycin decreased Th1 and Th17 cell populations and their associated cytokine production (IFN-γ, IL-17) in EAE mice.

Conclusions:

• Rapamycin exerts immunosuppressive effects in EAE by inhibiting the mTOR-STAT3 pathway.
• This inhibition leads to reduced Th1 and Th17 cell responses, crucial in MS pathogenesis.
• The findings offer insights into rapamycin's therapeutic potential for multiple sclerosis.